Syros Pharmaceuticals (SYRS) Competitors $0.03 0.00 (-1.94%) As of 03/27/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYRS vs. TSBX, BCLI, RLMD, TXMD, NEUP, ABVC, APLM, AIM, ONCO, and DWTXShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Turnstone Biologics (TSBX), Brainstorm Cell Therapeutics (BCLI), Relmada Therapeutics (RLMD), TherapeuticsMD (TXMD), Neuphoria Therapeutics Inc. - Common Stock (NEUP), ABVC BioPharma (ABVC), Apollomics (APLM), AIM ImmunoTech (AIM), Onconetix (ONCO), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Turnstone Biologics Brainstorm Cell Therapeutics Relmada Therapeutics TherapeuticsMD Neuphoria Therapeutics Inc. - Common Stock ABVC BioPharma Apollomics AIM ImmunoTech Onconetix Dogwood Therapeutics Turnstone Biologics (NASDAQ:TSBX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking. Do analysts rate TSBX or SYRS? Turnstone Biologics currently has a consensus price target of $0.45, indicating a potential upside of 10.32%. Syros Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 10,864.91%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media favor TSBX or SYRS? In the previous week, Syros Pharmaceuticals had 5 more articles in the media than Turnstone Biologics. MarketBeat recorded 6 mentions for Syros Pharmaceuticals and 1 mentions for Turnstone Biologics. Turnstone Biologics' average media sentiment score of 1.87 beat Syros Pharmaceuticals' score of 0.31 indicating that Turnstone Biologics is being referred to more favorably in the media. Company Overall Sentiment Turnstone Biologics Very Positive Syros Pharmaceuticals Neutral Do insiders & institutionals have more ownership in TSBX or SYRS? 52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer TSBX or SYRS? Syros Pharmaceuticals received 363 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 61.78% of users gave Syros Pharmaceuticals an outperform vote while only 44.44% of users gave Turnstone Biologics an outperform vote. CompanyUnderperformOutperformTurnstone BiologicsOutperform Votes444.44% Underperform Votes555.56% Syros PharmaceuticalsOutperform Votes36761.78% Underperform Votes22738.22% Which has stronger earnings and valuation, TSBX or SYRS? Turnstone Biologics has higher revenue and earnings than Syros Pharmaceuticals. Turnstone Biologics is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurnstone Biologics$19.31M0.49-$55.20M-$3.24-0.13Syros Pharmaceuticals$386K2.11-$164.57M-$3.03-0.01 Which has more volatility and risk, TSBX or SYRS? Turnstone Biologics has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Is TSBX or SYRS more profitable? Turnstone Biologics' return on equity of -105.99% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Turnstone BiologicsN/A -105.99% -87.27% Syros Pharmaceuticals N/A -3,369.56%-97.04% SummarySyros Pharmaceuticals beats Turnstone Biologics on 10 of the 17 factors compared between the two stocks. Remove Ads Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$816,000.00$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-0.017.2023.1319.03Price / Sales2.11226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.046.476.944.33Net Income-$164.57M$141.90M$3.20B$247.06M7 Day PerformanceN/A-3.20%-2.33%-0.37%1 Month PerformanceN/A-5.64%2.84%-3.85%1 Year PerformanceN/A-7.47%10.74%1.27% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.042 of 5 stars$0.03-1.9%$3.33+10,864.9%-99.5%$816,000.00$386,000.00-0.01120Short Interest ↑Gap UpTSBXTurnstone Biologics2.0853 of 5 stars$0.39+6.0%$0.45+14.2%-85.6%$9.11M$19.31M-0.1282BCLIBrainstorm Cell Therapeutics3.9085 of 5 stars$1.58-0.6%$30.00+1,798.7%-85.0%$9.01MN/A-0.3340Analyst ForecastNews CoverageRLMDRelmada Therapeutics3.9223 of 5 stars$0.29+0.7%$4.25+1,342.1%-93.5%$8.89MN/A-0.1010Earnings ReportNews CoverageTXMDTherapeuticsMD0.9245 of 5 stars$0.77+5.9%N/A-53.3%$8.86M$1.60M0.00420Short Interest ↓News CoverageNEUPNeuphoria Therapeutics Inc. - Common Stock1.9861 of 5 stars$5.00+5.9%$21.00+320.0%N/A$8.79M$662,715.000.00N/APositive NewsABVCABVC BioPharma1.4212 of 5 stars$0.65+0.7%N/A-33.4%$8.44M$509,788.00-0.7630Upcoming EarningsShort Interest ↓Positive NewsGap UpAPLMApollomics2.5969 of 5 stars$7.64-0.7%$200.00+2,519.5%-86.1%$8.30M$1.22M0.0045Short Interest ↓News CoveragePositive NewsGap UpAIMAIM ImmunoTech1.6676 of 5 stars$0.12+3.4%$2.75+2,191.7%-71.1%$8.25M$190,000.00-0.2620News CoverageGap UpONCOOnconetix0.5872 of 5 stars$0.13-1.6%N/A-98.4%$8.13M$1.87M0.0012Short Interest ↑Positive NewsGap DownDWTXDogwood TherapeuticsN/A$6.09-0.5%N/AN/A$8.11MN/A-0.935 Remove Ads Related Companies and Tools Related Companies TSBX Alternatives BCLI Alternatives RLMD Alternatives TXMD Alternatives NEUP Alternatives ABVC Alternatives APLM Alternatives AIM Alternatives ONCO Alternatives DWTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
